DocMorris AG (SWX:DOCM)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 959.29M +269.6% |
| Revenue (ttm) | 1.18B +11.3% |
| Net Income | -125.94M |
| EPS | -2.61 |
| Shares Out | 50.49M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 517,950 |
| Open | 19.30 |
| Previous Close | 18.74 |
| Day's Range | 18.68 - 19.50 |
| 52-Week Range | 3.92 - 19.50 |
| Beta | 1.87 |
| Analysts | Buy |
| Price Target | 13.97 (-26.47%) |
| Earnings Date | Mar 18, 2027 |
About DocMorris AG
DocMorris AG operates as an online pharmacy, telemedicine, and healthcare company in Switzerland and internationally. The company offers prescription and over-the-counter medicines, and consumer health products, as well as beauty and personal care products, nutritional supplements, painkillers, and first aid products. The company also provides professional health care services to doctors, pharmacies, insurers, and health institutions. It sells its products to online mail-order pharmacies, and private individuals under the DocMorris, PromoFarma ... [Read more]
Financial Performance
In 2025, DocMorris AG's revenue was 1.12 billion, an increase of 10.56% compared to the previous year's 1.02 billion. Losses were -134.40 million, 38.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for DOCM stock is "Buy." The 12-month stock price target is CHF 13.97, which is a decrease of -26.47% from the latest price.
News
DocMorris AG Press release: FY 2026
DocMorris AG issued a press release on November 12, 2026, disclosing material business information to investors.
DocMorris AG Slides: FY 2026
DocMorris AG has posted slides in relation to its FY 2026 quarterly earnings report, which was published on November 12, 2026.
DocMorris AG Earnings release: Q3 2026
DocMorris AG released its Q3 2026 earnings on October 15, 2026, summarizing the period's financial results.
DocMorris AG Transcript: Global Markets Forum Conference
Rx momentum and cost control supported higher FY 2026 revenue guidance, while H2 EBITDA breakeven remains the target. AI-led efficiency, telemedicine and retail media are central to the longer-term platform strategy.
DocMorris AG Slides: Global Markets Forum Conference
DocMorris AG has posted slides in relation to its latest quarterly earnings report, which was published on October 7, 2026.
DocMorris downgraded to Hold from Buy at Jefferies
Jefferies downgraded DocMorris (ZRSEF) to Hold from Buy with a price target of CHF 11, up from CHF 9.50. After the stock’s strong year-to-date re-rating, much of the improved growth…
DocMorris price target raised to CHF 12.50 from CHF 11.50 at Deutsche Bank
Deutsche Bank analyst Jan Koch raised the firm’s price target on DocMorris (ZRSEF) to CHF 12.50 from CHF 11.50 and keeps a Buy rating on the shares. Published first on…
DocMorris AG Earnings Call Transcript: Q2 2026
H1 2026 saw double-digit revenue growth, record Rx and digital services expansion, and improved margins. AI-driven efficiencies and cost controls support raised guidance, with EBITDA breakeven expected in 2026 and free cash flow breakeven in 2027.
DocMorris AG Quarterly report: Q2 2026
DocMorris AG has published its Q2 2026 quarterly earnings report on August 19, 2026.
DocMorris AG Earnings release: Q2 2026
DocMorris AG released its Q2 2026 earnings on August 19, 2026, summarizing the period's financial results.
DocMorris AG Slides: Q2 2026
DocMorris AG has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 19, 2026.
DocMorris upgraded to Neutral from Sell at UBS
UBS analyst Sebastian Vogel upgraded DocMorris (ZRSEF) to Neutral from Sell with a price target of CHF 10.70, up from CHF 4. The firm sees an improving margin backdrop for…
DocMorris AG Earnings release: Q2 2026
DocMorris AG released its Q2 2026 earnings on July 15, 2026, summarizing the period's financial results.
DocMorris upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank upgraded DocMorris (ZRSEF) to Buy from Hold with a CHF 11.50 price target The firm sees an increasingly attractive risk/reward at current share levels given the company’s likely…
DocMorris AG Earnings Call Transcript: Q1 2026
Revenue grew 10.7% year-over-year, led by 30.4% Rx and 63.1% digital services growth. Adjusted EBITDA improved by CHF 9.8 million to CHF -6.3 million, with breakeven targeted in 2026. Guidance for revenue and EBITDA is confirmed, with strong momentum in all key segments.
DocMorris AG Earnings release: Q1 2026
DocMorris AG released its Q1 2026 earnings on April 16, 2026, summarizing the period's financial results.
DocMorris AG Slides: Q1 2026
DocMorris AG has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 16, 2026.
DocMorris price target lowered to CHF 4.45 from CHF 8.10 at Berenberg
Berenberg lowered the firm’s price target on DocMorris (ZRSEF) to CHF 4.45 from CHF 8.10 and keeps a Hold rating on the shares.
DocMorris price target lowered to CHF 4.50 from CHF 7 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on DocMorris (ZRSEF) to CHF 4.50 from CHF 7 and keeps a Hold rating on the shares.
DocMorris AG Earnings Call Transcript: H2 2025
Revenue grew 11.1% in 2025, driven by Rx (+33%) and digital services (+110%), with strong margin gains and a robust liquidity position. EBITDA breakeven is targeted for 2026, supported by platform expansion, cost control, and a new Google partnership.
DocMorris AG Annual report: H2 2025
DocMorris AG has published its H2 2025 annual report on March 19, 2026.
DocMorris AG Slides: H2 2025
DocMorris AG has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 19, 2026.
DocMorris AG Earnings release: Q4 2025
DocMorris AG released its Q4 2025 earnings on January 20, 2026, summarizing the period's financial results.
DocMorris AG Earnings release: Q3 2025
DocMorris AG released its Q3 2025 earnings on October 16, 2025, summarizing the period's financial results.
DocMorris AG Earnings Call Transcript: H1 2025
Strong Rx and TeleClinic growth drove a 10.2% revenue increase in H1 2025, with gross margin up 70 bps and a solid balance sheet after a CHF 200 million capital raise. Full-year guidance is confirmed, with sequential EBITDA improvement expected as marketing spend is optimized.